Merck to push for approval of HIV combo after Phase III success

Merck & Co (MSD) is looking to file for approval of its human immunodeficiency virus (HIV) treatment after two positive Phase III trial readouts.

Its once-daily oral combination of the approved drug Pifeltro (doravirine) and its investigational therapy islatravir (DOR/ISL), maintained HIV-1 viral suppression after 48 weeks in two pivotal trials.